Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Du

Showing results (571-580 of 818) with videos related to

Pageof 82
Sort By:
Zhonghua Yi Xue Za Zhi|June 15, 2026
[Role of exogenous supplementation of umbilical cord blood immune cells in reconstructing immune function and restoring hematopoietic function in elderly high-risk myeloid neoplasms patients]C X Du, H Q Zhang, Y H Zhang, et al.
Nature|July 23, 2003
Identification of Lps2 as a key transducer of MyD88-independent TIR signallingK Hoebe, X Du, P Georgel, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|June 14, 2023
[Analysis of dyslipidemia management status in atrial fibrillation patients with very high and high risk of atherosclerotic cardiovascular disease]S S Chang, J H Wu, J Cui, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|April 20, 2021
[Causes of death and influencing factors of atrial fibrillation patients undergoing anticoagulation therapy]C Hua, C Jiang, L He, et al.
Zhonghua Yi Xue Za Zhi|July 1, 2024
[Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model]J Y Ma, Y H Zhang, G S Teng, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 17, 2016
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trialK Kalinsky, T Zheng, H Hibshoosh, et al.
Cell Discovery|June 6, 2017
MOF as an evolutionarily conserved histone crotonyltransferase and transcriptional activation by histone acetyltransferase-deficient and crotonyltransferase-competent CBP/p300Xiaoguang Liu, Wei Wei, Yuting Liu, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|February 3, 2020
[Impact of change of ideal cardiovascular behavior and related factors on healthy vascular aging]C R Zhu, X Du, Y Liu, et al.
The Oncologist|September 20, 2022
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Clinical Drug Investigation|June 13, 2022
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell CarcinomaDaniel M Geynisman, Mauricio Burotto, Camillo Porta, et al.
Pageof 82

Showing results (571-580 of 818) with videos related to

Sort By:
Pageof 82
Zhonghua Yi Xue Za Zhi|June 15, 2026
[Role of exogenous supplementation of umbilical cord blood immune cells in reconstructing immune function and restoring hematopoietic function in elderly high-risk myeloid neoplasms patients]C X Du, H Q Zhang, Y H Zhang, et al.
Nature|July 23, 2003
Identification of Lps2 as a key transducer of MyD88-independent TIR signallingK Hoebe, X Du, P Georgel, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|June 14, 2023
[Analysis of dyslipidemia management status in atrial fibrillation patients with very high and high risk of atherosclerotic cardiovascular disease]S S Chang, J H Wu, J Cui, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|April 20, 2021
[Causes of death and influencing factors of atrial fibrillation patients undergoing anticoagulation therapy]C Hua, C Jiang, L He, et al.
Zhonghua Yi Xue Za Zhi|July 1, 2024
[Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model]J Y Ma, Y H Zhang, G S Teng, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 17, 2016
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trialK Kalinsky, T Zheng, H Hibshoosh, et al.
Cell Discovery|June 6, 2017
MOF as an evolutionarily conserved histone crotonyltransferase and transcriptional activation by histone acetyltransferase-deficient and crotonyltransferase-competent CBP/p300Xiaoguang Liu, Wei Wei, Yuting Liu, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|February 3, 2020
[Impact of change of ideal cardiovascular behavior and related factors on healthy vascular aging]C R Zhu, X Du, Y Liu, et al.
The Oncologist|September 20, 2022
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Clinical Drug Investigation|June 13, 2022
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell CarcinomaDaniel M Geynisman, Mauricio Burotto, Camillo Porta, et al.
Pageof 82